Back
ACVC Premium Access

Prasugrel and ticagrelor are equal in PCI for NSTEMI and STEMI - CON.

Session: Debating Oral P2Y12 inhibitors Use – are there differences across the Atlantic?
Topic: Acute Coronary Syndromes
Speaker: Professor A. Kastrati (Munich, DE)
Event: ACVC 2021

Congress Presentation

About the speaker

Professor Adnan Kastrati

German Heart Center Muenchen Technical University of Munich, Munich (Germany)
11 presentations
0 follower

5 more presentations in this session

Pre-treatment with P2Y12 inhibitors in ACS is unnecessary and risky – PRO.

Speaker: Professor K. Huber (Vienna, AT)

Access
Slides
Video
Thumbnail

Pre-treatment with P2Y12 inhibitors in ACS is unnecessary and risky – CON.

Speaker: Professor C. Granger (Durham, US)

Access
Slides
Video
Thumbnail

Pre-treatment with P2Y12 inhibitors in ACS is unnecessary and risky – Discussion.

Access
Thumbnail

Prasugrel and ticagrelor are equal in PCI for NSTEMI and STEMI - PRO.

Speaker: Professor R. Welsh (Edmonton, CA)

Access
Slides
Video
Thumbnail

Prasugrel and ticagrelor are equal in PCI for NSTEMI and STEMI - Discussion.

Access
Thumbnail

Access the full session

Debating Oral P2Y12 inhibitors Use – are there differences across the Atlantic?

Speakers: Professor A. Kastrati, Professor K. Huber, Professor C. Granger, Professor R. Welsh
Access
Video
Thumbnail

About the event

Image

ACVC 2021

13 March - 14 March 2021

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb